Halifax, Nova Scotia, September 18, 2017 – Stockport Exploration Inc. (TSXV: SPT) (“Stockport” or the “Company”) is pleased to announce that it has entered into a letter of intent dated September [...]
Sona Nanotech Ltd. has leveraged its team’s unique knowledge and experience with novel surface chemistry methods and surfactants to create a disruptive leap forward in metallic nanoparticle technology.
Co-founders Dr. Gerrard Marangoni, Dr. Kulbir Singh, and Dr. Michael McAlduff recognized the role that gold nanoparticles can play in a variety of life sciences applications, e.g., in-vivo 3-D imaging, GNR-enabled diagnostic test products and other cutting edge medical applications. Gold nanorods can be enabling technologies for non-invasive targeted cell, tumor, tissue and organ treatments such as photothermal cancer cell destruction, and location specific drug and pain treatment.
Over the last 30 years, there has been incredible progress within the research community working with gold nanoparticles in the areas of photothermal cancer treatment, diagnostic imaging, drug delivery and other areas. CTAB is a major concern in advancing the existing research into human use,” stated Dr. Ephraim Honig, COO of Strem Chemicals. “We are excited to be the first to bring to market gold nanoparticles that can help bring decades of research closer to the reality of life changing procedures.”